Lineage Cell Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Lineage Cell Therapeutics, Inc. (LCTX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -0.71% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2026-03-05
- Lineage Cell Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2025 was -0.71%.
- Lineage Cell Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -2.00%, a 300.00% decline from fiscal 2023.
- Lineage Cell Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was 1.00%, a 66.67% decline from fiscal 2022.
- Lineage Cell Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was 3.00%, a 200.00% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -0.71% 10-K · filed 2026-03-05 | |
| 2024-12-31 | -2.00% 10-K · filed 2026-03-05 | |
| 2023-12-31 | 1.00% 10-K · filed 2025-03-10 | -1.00% 10-K · filed 2024-03-07 |
| 2022-12-31 | 3.00% 10-K · filed 2024-03-07 | |
| 2021-12-31 | 1.00% 10-K · filed 2023-03-09 | |
| 2020-12-31 | 1.00% 10-K · filed 2022-03-10 | |
| 2019-12-31 | 3.00% 10-K · filed 2021-03-11 | |
| 2018-12-31 | 1.00% 10-K · filed 2020-03-12 | |
| 2017-12-31 | 2.00% 10-K · filed 2019-03-14 | |
| 2016-12-31 | -3.00% 10-K · filed 2018-03-15 | |
| 2015-12-31 | 2.00% 10-K · filed 2018-03-15 | |
| 2014-12-31 | 3.00% 10-K · filed 2017-03-16 | |
| 2013-12-31 | -1.00% 10-K · filed 2014-03-17 | |
| 2012-12-31 | 3.00% 10-K · filed 2014-03-17 | |
| 2011-12-31 | 0.00% 10-K · filed 2014-03-17 | |
| 2010-12-31 | 0.00% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |